In August 2025, the U.S. stock market delivered a steady performance, with the S&P 500 index rising by 1.9% over the month. However, amid this moderate overall gain, two constituent stocks significantly outperformed the broader market: chemical company Albemarle Corporation (ALB) and healthcare giant UnitedHealth Group (UNH).
Albemarle Corporation emerged as the best-performing stock in the S&P 500 with a monthly gain of over 25%. Its strong stock performance was primarily driven by two factors. On one hand, Chinese battery manufacturer CATL shut down operations at one of the world’s largest lithium mines, significantly impacting the short-term global supply dynamics of lithium resources. As a major global owner and operator of lithium mines, Albemarle attracted investor favor due to heightened demand expectations for its products—particularly lithium metal used in electric vehicle batteries. On the other hand, Albemarle’s financial results for the second quarter of 2025, released at the end of July, exceeded market expectations. The company reported sales of $1.3 billion and non-GAAP earnings per share of $0.11, significantly outperforming analysts’ earlier forecast of a $0.84 per share loss. This provided momentum for its stock rally in early August.
UnitedHealth Group followed closely behind, with its stock rising just over 24% in August. The immediate catalyst for its surge was the disclosure that investment master Warren Buffett’s Berkshire Hathaway had purchased 5 million shares of the company. This move was interpreted by the market as a sign of recognition from the investment giant of UnitedHealth’s long-term value. However, it is worth noting that despite the substantial rebound during the month, UnitedHealth’s stock price was still down approximately 48% from its peak in April of this year. The earlier pressure on its stock had been due to a disappointing first-quarter earnings report and a subsequent downward revision of its full-year profit guidance. The company significantly lowered its 2025 earnings per share expectation from the previously projected $29.50–$30.00 at the end of last year to “at least $16.00,” primarily driven by unexpectedly high cost pressures in businesses such as its Medicare Advantage plans.
Although Albemarle and UnitedHealth delivered outstanding performances in August, it is important to recognize that single-month stock price movements are often driven by specific events, market sentiment, or short-term news, which may not always fully reflect a company’s intrinsic value or long-term fundamentals. For investors considering investments in such short-term outperformers, independent in-depth research remains essential to comprehensively evaluate the company’s business model, financial condition, industry competitive landscape, and long-term growth prospects.
